首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody
【2h】

Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody

机译:广泛中和的人抗体穿透丙型肝炎病毒E2糖蛋白的糖盾的结构基础

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. A challenge for HCV vaccine development is to identify conserved epitopes able to elicit protective antibodies against this highly diverse virus. Glycan shielding is a mechanism by which HCV masks such epitopes on its E2 envelope glycoprotein. Antibodies to the E2 region comprising residues 412–423 (E2412–423) have broadly neutralizing activities. However, an adaptive mutation in this linear epitope, N417S, is associated with a glycosylation shift from Asn-417 to Asn-415 that enables HCV to escape neutralization by mAbs such as HCV1 and AP33. By contrast, the human mAb HC33.1 can neutralize virus bearing the N417S mutation. To understand how HC33.1 penetrates the glycan shield created by the glycosylation shift to Asn-415, we determined the structure of this broadly neutralizing mAb in complex with its E2412–423 epitope to 2.0 Å resolution. The conformation of E2412–423 bound to HC33.1 is distinct from the β-hairpin conformation of this peptide bound to HCV1 or AP33, because of disruption of the β-hairpin through interactions with the unusually long complementarity-determining region 3 of the HC33.1 heavy chain. Whereas Asn-415 is buried by HCV1 and AP33, it is solvent-exposed in the HC33.1-E2412–423 complex, such that glycosylation of Asn-415 would not prevent antibody binding. Furthermore, our results highlight the structural flexibility of the E2412–423 epitope, which may serve as an immune evasion strategy to impede induction of antibodies targeting this site by reducing its antigenicity.
机译:丙型肝炎病毒(HCV)是肝硬化和肝细胞癌的主要原因。 HCV疫苗开发面临的挑战是鉴定能够引发针对这种高度多样化病毒的保护性抗体的保守表位。聚糖屏蔽是HCV掩盖其E2包膜糖蛋白上的此类表位的机制。包含残基412-423(E2412-423)的E2区抗体具有广泛的中和活性。但是,此线性表位N417S中的适应性突变与从Asn-417到Asn-415的糖基化转变相关,该转变使HCV能够被诸如HCV1和AP33的单克隆抗体中和。相反,人mAb HC33.1可以中和带有N417S突变的病毒。为了了解HC33.1如何穿透糖基化向Asn-415转移而产生的聚糖屏蔽,我们确定了这种广泛中和的mAb及其E2412–423表位的复合物的结构,分辨率为2.0。与HC33.1结合的E2412–423的构象不同于与HCV1或AP33结合的该肽的β-发夹构象,这是因为β-发夹通过与HC33异常长的互补决定区3的相互作用而破坏.1重链。 Asn-415被HCV1和AP33掩埋,但是它被溶剂暴露在HC33.1-E2412-423复合物中,因此Asn-415的糖基化不会阻止抗体结合。此外,我们的结果突出了E2412–423表位的结构灵活性,这可能是一种免疫逃避策略,可通过降低抗原性来阻止针对该位点的抗体的诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号